Report Detail
Global Hormone Refractory Prostate Cancer (HRPCA) Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
- RnM2772940 |
- 17 January, 2019 |
- Global |
- 102 Pages |
- GIR (Global Info Research) |
- Pharma & Healthcare
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
Scope of the Report:
This report focuses on the Hormone Refractory Prostate Cancer (HRPCA) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Hormone Refractory Prostate Cancer (HRPCA) is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Surgery
Market Segment by Applications, can be divided into
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
There are 15 Chapters to deeply display the global Hormone Refractory Prostate Cancer (HRPCA) market.
Chapter 1, to describe Hormone Refractory Prostate Cancer (HRPCA) Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Hormone Refractory Prostate Cancer (HRPCA), with sales, revenue, and price of Hormone Refractory Prostate Cancer (HRPCA), in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Hormone Refractory Prostate Cancer (HRPCA), for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Hormone Refractory Prostate Cancer (HRPCA) market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Hormone Refractory Prostate Cancer (HRPCA) sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Table of Contents
1 Market Overview
- 1.1 Hormone Refractory Prostate Cancer (HRPCA) Introduction
- 1.2 Market Analysis by Type
- 1.2.1 Chemotherapy
- 1.2.2 Hormonal Therapy
- 1.2.3 Immunotherapy
- 1.2.4 Radiation Therapy
- 1.2.5 Surgery
- 1.3 Market Analysis by Applications
- 1.3.1 Hospitals
- 1.3.2 Ambulatory Surgical Centers
- 1.3.3 Specialty Clinics
- 1.4 Market Analysis by Regions
- 1.4.1 North America (United States, Canada and Mexico)
- 1.4.1.1 United States Market States and Outlook (2013-2023)
- 1.4.1.2 Canada Market States and Outlook (2013-2023)
- 1.4.1.3 Mexico Market States and Outlook (2013-2023)
- 1.4.2 Europe (Germany, France, UK, Russia and Italy)
- 1.4.2.1 Germany Market States and Outlook (2013-2023)
- 1.4.2.2 France Market States and Outlook (2013-2023)
- 1.4.2.3 UK Market States and Outlook (2013-2023)
- 1.4.2.4 Russia Market States and Outlook (2013-2023)
- 1.4.2.5 Italy Market States and Outlook (2013-2023)
- 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- 1.4.3.1 China Market States and Outlook (2013-2023)
- 1.4.3.2 Japan Market States and Outlook (2013-2023)
- 1.4.3.3 Korea Market States and Outlook (2013-2023)
- 1.4.3.4 India Market States and Outlook (2013-2023)
- 1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
- 1.4.4 South America, Middle East and Africa
- 1.4.4.1 Brazil Market States and Outlook (2013-2023)
- 1.4.4.2 Egypt Market States and Outlook (2013-2023)
- 1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
- 1.4.4.4 South Africa Market States and Outlook (2013-2023)
- 1.4.4.5 Nigeria Market States and Outlook (2013-2023)
- 1.4.1 North America (United States, Canada and Mexico)
- 1.5 Market Dynamics
- 1.5.1 Market Opportunities
- 1.5.2 Market Risk
- 1.5.3 Market Driving Force
2 Manufacturers Profiles
- 2.1 Astellas Inc
- 2.1.1 Business Overview
- 2.1.2 Hormone Refractory Prostate Cancer (HRPCA) Type and Applications
- 2.1.2.1 Product A
- 2.1.2.2 Product B
- 2.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
- 2.2 Sanofi S.A
- 2.2.1 Business Overview
- 2.2.2 Hormone Refractory Prostate Cancer (HRPCA) Type and Applications
- 2.2.2.1 Product A
- 2.2.2.2 Product B
- 2.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
- 2.3 Dendreon Corporation, Bayer AG
- 2.3.1 Business Overview
- 2.3.2 Hormone Refractory Prostate Cancer (HRPCA) Type and Applications
- 2.3.2.1 Product A
- 2.3.2.2 Product B
- 2.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
- 2.4 Johnson & Johnson
- 2.4.1 Business Overview
- 2.4.2 Hormone Refractory Prostate Cancer (HRPCA) Type and Applications
- 2.4.2.1 Product A
- 2.4.2.2 Product B
- 2.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
- 3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Manufacturer (2016-2017)
- 3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Manufacturer (2016-2017)
- 3.3 Market Concentration Rate
- 3.3.1 Top 3 Hormone Refractory Prostate Cancer (HRPCA) Manufacturer Market Share in 2017
- 3.3.2 Top 6 Hormone Refractory Prostate Cancer (HRPCA) Manufacturer Market Share in 2017
- 3.4 Market Competition Trend
4 Global Hormone Refractory Prostate Cancer (HRPCA) Market Analysis by Regions
- 4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Market Share by Regions
- 4.1.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Regions (2013-2018)
- 4.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Regions (2013-2018)
- 4.2 North America Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 4.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 4.4 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 4.5 South America Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 4.6 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
5 North America Hormone Refractory Prostate Cancer (HRPCA) by Countries
- 5.1 North America Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Market Share by Countries
- 5.1.1 North America Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Countries (2013-2018)
- 5.1.2 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Countries (2013-2018)
- 5.2 United States Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 5.3 Canada Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 5.4 Mexico Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
6 Europe Hormone Refractory Prostate Cancer (HRPCA) by Countries
- 6.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Market Share by Countries
- 6.1.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Countries (2013-2018)
- 6.1.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Countries (2013-2018)
- 6.2 Germany Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 6.3 UK Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 6.4 France Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 6.5 Russia Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 6.6 Italy Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
7 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) by Countries
- 7.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Market Share by Countries
- 7.1.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Countries (2013-2018)
- 7.1.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Countries (2013-2018)
- 7.2 China Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 7.3 Japan Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 7.4 Korea Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 7.5 India Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 7.6 Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
8 South America Hormone Refractory Prostate Cancer (HRPCA) by Countries
- 8.1 South America Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Market Share by Countries
- 8.1.1 South America Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Countries (2013-2018)
- 8.1.2 South America Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Countries (2013-2018)
- 8.2 Brazil Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 8.3 Argentina Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 8.4 Colombia Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
9 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) by Countries
- 9.1 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Market Share by Countries
- 9.1.1 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Countries (2013-2018)
- 9.1.2 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Countries (2013-2018)
- 9.2 Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 9.3 UAE Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 9.4 Egypt Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 9.5 Nigeria Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
- 9.6 South Africa Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
10 Global Hormone Refractory Prostate Cancer (HRPCA) Market Segment by Type
- 10.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Market Share by Type (2013-2018)
- 10.1.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Type (2013-2018)
- 10.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Type (2013-2018)
- 10.2 Chemotherapy Sales Growth and Price
- 10.2.1 Global Chemotherapy Sales Growth (2013-2018)
- 10.2.2 Global Chemotherapy Price (2013-2018)
- 10.3 Hormonal Therapy Sales Growth and Price
- 10.3.1 Global Hormonal Therapy Sales Growth (2013-2018)
- 10.3.2 Global Hormonal Therapy Price (2013-2018)
- 10.4 Immunotherapy Sales Growth and Price
- 10.4.1 Global Immunotherapy Sales Growth (2013-2018)
- 10.4.2 Global Immunotherapy Price (2013-2018)
- 10.5 Radiation Therapy Sales Growth and Price
- 10.5.1 Global Radiation Therapy Sales Growth (2013-2018)
- 10.5.2 Global Radiation Therapy Price (2013-2018)
- 10.6 Surgery Sales Growth and Price
- 10.6.1 Global Surgery Sales Growth (2013-2018)
- 10.6.2 Global Surgery Price (2013-2018)
11 Global Hormone Refractory Prostate Cancer (HRPCA) Market Segment by Application
- 11.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Application (2013-2018)
- 11.2 Hospitals Sales Growth (2013-2018)
- 11.3 Ambulatory Surgical Centers Sales Growth (2013-2018)
- 11.4 Specialty Clinics Sales Growth (2013-2018)
12 Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
- 12.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Growth Rate (2018-2023)
- 12.2 Hormone Refractory Prostate Cancer (HRPCA) Market Forecast by Regions (2018-2023)
- 12.2.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
- 12.2.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
- 12.2.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
- 12.2.4 South America Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
- 12.2.5 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
- 12.3 Hormone Refractory Prostate Cancer (HRPCA) Market Forecast by Type (2018-2023)
- 12.3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Forecast by Type (2018-2023)
- 12.3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Type (2018-2023)
- 12.4 Hormone Refractory Prostate Cancer (HRPCA) Market Forecast by Application (2018-2023)
- 12.4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Forecast by Application (2018-2023)
- 12.4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
- 13.1 Sales Channel
- 13.1.1 Direct Marketing
- 13.1.2 Indirect Marketing
- 13.1.3 Marketing Channel Future Trend
- 13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
- 15.1 Methodology
Summary:
Get latest Market Research Reports on Hormone Refractory Prostate Cancer (HRPCA) . Industry analysis & Market Report on Hormone Refractory Prostate Cancer (HRPCA) is a syndicated market report, published as Global Hormone Refractory Prostate Cancer (HRPCA) Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024. It is complete Research Study and Industry Analysis of Hormone Refractory Prostate Cancer (HRPCA) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
